BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18303433)

  • 1. The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
    Morgensztern D; Goodgame B; Baggstrom MQ; Gao F; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):135-9. PubMed ID: 18303433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
    Tönnies S; Bauer TT; Misch D; Boch C; Blum T; Bittner RC; Förster GJ; Kollmeier J
    Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
    Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
    Gauger J; Patz EF; Coleman RE; Herndon JE
    J Thorac Oncol; 2007 Jun; 2(6):499-505. PubMed ID: 17545844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
    Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
    Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
    Liu SW; Yu JM; Xing LG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (stage III and IV) non-small cell lung cancer.
    Kim YS; Lee MK; Kim SJ; Kim IJ; Kim YK; Jo WS; Park SK
    Neoplasma; 2010; 57(3):241-6. PubMed ID: 20353275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.
    Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
    J Clin Oncol; 2012 Aug; 30(22):2725-30. PubMed ID: 22753917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer.
    Abe K; Baba S; Kaneko K; Isoda T; Yabuuchi H; Sasaki M; Sakai S; Yoshino I; Honda H
    Clin Imaging; 2009; 33(2):90-5. PubMed ID: 19237050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
    Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
    Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT.
    Pauls S; Buck AK; Hohl K; Halter G; Hetzel M; Blumstein NM; Mottaghy FM; Glatting G; Krüger S; Sunder-Plassmann L; Möller P; Hombach V; Brambs HJ; Reske SN
    Nuklearmedizin; 2007; 46(1):9-14; quiz N1-2. PubMed ID: 17299649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of FDG-PET-induced treatment choices on long-term outcome in non-small cell lung cancer.
    Wauters I; Stroobants S; De Leyn P; D'Hoore I; Nackaerts K; Dooms C; Vansteenkiste J
    Respiration; 2010; 79(2):97-104. PubMed ID: 19420903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
    Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.